Atara Biotherapeutics, Inc. (NASDAQ: ATRA) today announced receipt of positive regulatory feedback from Health Canada for ATA129, the Company’s most ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE